<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Erasca Inc — News on 6ix</title>
    <link>https://6ix.com/company/erasca-inc</link>
    <description>Latest news and press releases for Erasca Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 20:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/erasca-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835640278dffbe2df0ef7cd.webp</url>
      <title>Erasca Inc</title>
      <link>https://6ix.com/company/erasca-inc</link>
    </image>
    <item>
      <title>Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors</guid>
      <pubDate>Mon, 27 Apr 2026 20:01:00 GMT</pubDate>
      <description>Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs Preliminary data suggest ERAS-0015 may combine safely</description>
    </item>
    <item>
      <title>Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-reports-fourth-quarter-and-full-year-2025-business-updates-and-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-reports-fourth-quarter-and-full-year-2025-business-updates-and-financial-results</guid>
      <pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
      <description>Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN D</description>
    </item>
    <item>
      <title>Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-china-hong-kong-and-macau</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-china-hong-kong-and-macau</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its</description>
    </item>
    <item>
      <title>Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-and-tango-therapeutics-enter-into-clinical-collaboration-to-evaluate-combination-of-eras-0015-and-vopimetostat-11</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-and-tango-therapeutics-enter-into-clinical-collaboration-to-evaluate-combination-of-eras-0015-and-vopimetostat-11</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will</description>
    </item>
    <item>
      <title>Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-issuance-of-a-us-patent-covering-pan-kras-inhibitor-eras-4001</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-issuance-of-a-us-patent-covering-pan-kras-inhibitor-eras-4001</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP</description>
    </item>
    <item>
      <title>Erasca to Present at Upcoming Conferences in February</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-present-upcoming-conferences-february-2026-02-05</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-present-upcoming-conferences-february-2026-02-05</guid>
      <pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,</description>
    </item>
    <item>
      <title>Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-closing-upsized-public-210100607</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-closing-upsized-public-210100607</guid>
      <pubDate>Fri, 23 Jan 2026 21:01:00 GMT</pubDate>
      <description>SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The s</description>
    </item>
    <item>
      <title>Erasca Announces Pricing of Upsized Public Offering of Common Stock</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-pricing-upsized-public-015400698</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-pricing-upsized-public-015400698</guid>
      <pubDate>Thu, 22 Jan 2026 01:54:00 GMT</pubDate>
      <description>SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offerin</description>
    </item>
    <item>
      <title>Erasca Announces Proposed Public Offering of $150 Million of Common Stock</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-proposed-public-offering-210100621</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-proposed-public-offering-210100621</guid>
      <pubDate>Tue, 20 Jan 2026 21:01:00 GMT</pubDate>
      <description>SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are</description>
    </item>
    <item>
      <title>Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-promising-early-clinical-data-eras-0015-and-2026-2027-milestones</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-promising-early-clinical-data-eras-0015-and-2026-2027-milestones</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety</description>
    </item>
    <item>
      <title>Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,</description>
    </item>
    <item>
      <title>Erasca to Present at the 8th Annual Evercore Healthcare Conference</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-present-8th-annual-evercore-healthcare-conference-2025-11-25</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-present-8th-annual-evercore-healthcare-conference-2025-11-25</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,</description>
    </item>
    <item>
      <title>Erasca Reports Third Quarter 2025 Business Updates and Financial Results</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-reports-third-quarter-2025-business-updates-and-financial-results-2025-11-12</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-reports-third-quarter-2025-business-updates-and-financial-results-2025-11-12</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with</description>
    </item>
    <item>
      <title>Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-issuance-us-patent-covering-pan-ras-molecular-glue-eras-0015-2025-11</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-issuance-us-patent-covering-pan-ras-molecular-glue-eras-0015-2025-11</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for</description>
    </item>
    <item>
      <title>Erasca to Present at Upcoming Conferences in November</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-present-upcoming-conferences-november-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-present-upcoming-conferences-november-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,</description>
    </item>
    <item>
      <title>Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-present-morgan-stanley-23rd-annual-global-healthcare-conference-2025-09-02</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-present-morgan-stanley-23rd-annual-global-healthcare-conference-2025-09-02</guid>
      <pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,</description>
    </item>
    <item>
      <title>Erasca Reports Second Quarter 2025 Business Updates and Financial Results</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-reports-second-quarter-2025-business-updates-and-financial-results-2025-08-12</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-reports-second-quarter-2025-business-updates-and-financial-results-2025-08-12</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting</description>
    </item>
    <item>
      <title>Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-announces-ind-clearance-potential-first-class-and-best-class-pan-kras</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-announces-ind-clearance-potential-first-class-and-best-class-pan-kras</guid>
      <pubDate>Mon, 02 Jun 2025 04:00:00 GMT</pubDate>
      <description>Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1</description>
    </item>
    <item>
      <title>Erasca to Present at Upcoming Investor Conferences in June</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-present-upcoming-investor-conferences-june-2025-05-29</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-present-upcoming-investor-conferences-june-2025-05-29</guid>
      <pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,</description>
    </item>
    <item>
      <title>Erasca Reports First Quarter 2025 Business Updates and Financial Results</title>
      <link>https://6ix.com/company/erasca-inc/news/erasca-reports-first-quarter-2025-business-updates-and-financial-results-2025-05-13</link>
      <guid isPermaLink="true">https://6ix.com/company/erasca-inc/news/erasca-reports-first-quarter-2025-business-updates-and-financial-results-2025-05-13</guid>
      <pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
      <description>Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and</description>
    </item>
  </channel>
</rss>